Colorectal Cancer Epidemiology Analysis and Forecast, 2021-2031

Pages: 53 Published: June 29, 2022 Report Code: GDHCER298-22

  • Overview
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    iSpeech.org

The total number of cases affected by colorectal cancer was 3,183,569 in 2021. The number of cases is expected to grow at an AGR of more than 3% during the forecast period. The Colorectal Cancer Epidemiology Analysis and Forecast market research report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CRC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). The report includes a 10-year epidemiology forecast for the diagnosed incident cases of CRC. The diagnosed incident cases of CRC are segmented by age (18–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, 70–79 years, and 80 years and older) and sex.

Colorectal Cancer Market Outlook

Colorectal Cancer Market Outlook

For more insights on colorectal cancer market forecast data, download a free report sample

What are the market dynamics in the colorectal cancer market?

Although research studies have found several factors that can increase the risk of CRC, exactly how all those factors might cause this cancer remains unclear. A combination of genetic and environmental factors is most likely responsible for CRC. According to research in 2022, around a significant percentage of CRC cases develop for no clear reason, while a small percent seem to result from inherited syndromes, and a significant percent happen in family clusters. Among the non-modifiable risk factors of CRC are older age; male sex; being of African or Ashkenazi Jewish descent; family or personal history of CRC, polyps, or inflammatory bowel disease (IBD); and having an inherited syndrome due to gene mutations such as Lynch syndrome, also referred as hereditary non-polyposis CRC (HNPCC), and familial adenomatous polyposis. Many lifestyle-related modifiable factors are associated to CRC. Being overweight or obese, physical inactivity, eating a low-fiber and high-fat diet with red and processed meat regularly, sugary drinks, smoking, and alcohol are all linked to CRC (American Cancer Society, 2020b). In fact, the links between diet, exercise, and weight and CRC risk are some of the strongest for any type of cancer. In addition, type 2 diabetes, hypertension, chronic obstructive pulmonary disease (COPD), and congestive heart failure (CHF) are common comorbidities in CRC patients.

What are the key age segments in the colorectal cancer market?

The key age segments in the colorectal cancer market are 18-29 years, 30-39 years, 40-49 ears, 50-59 years, 60-69 years, 70-79 years, >80 years. In 2021, for the 8MM combined, adults ages 70–79 years contributed the highest proportion of the diagnosed incident cases of CRC.

Colorectal cancer market, by age group

Colorectal cancer market, by age group

For more age group insights, download a free report sample

What are the key stages in the colorectal cancer market?

The key stages in the colorectal cancer market are stage I, stage II, stage III, and stage IV. In the 8MM, the highest number of diagnosed incident cases of CRC was in stage II, followed by stage III and stage I.

Colorectal cancer market, by stages

Colorectal cancer market, by stages

For more stage insights, download a free report sample

Market report overview

Total colorectal cancer cases (2021) 3,183,569
Growth rate (AGR) >2% (2021-2031)
Key age segments 18-29 years, 30-39 years, 40-49 ears, 50-59 years, 60-69 years, 70-79 years, >80 years
Key stages Stage I, Stage II, Stage III, and Stage IV

Scope

  • The Colorectal Cancer (CRC) Epidemiology Report and Model provide an overview of the risk factors and global trends of CRC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China).
  • The report includes a 10-year epidemiology forecast for the diagnosed incident cases of CRC. The diagnosed incident cases of CRC are segmented by age (18–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, 70–79 years, and 80 years and older) and sex. The diagnosed incident cases are further segmented by the American Joint Committee on Cancer (AJCC) stage at diagnosis (stage I, stage II, stage III, and stage IV), by recurrence of stages I–III into stage IV disease, and by molecular markers. The report also provides a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of CRC.
  • The CRC epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

  • The Colorectal Cancer Epidemiology series will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global CRC market.
  • Quantify patient populations in the global CRC market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CRC therapeutics in each of the markets covered.
  • Understand magnitude of CRC population by stage at diagnosis, recurrence of stages I–III into stage IV disease, and molecular markers.

Table of Contents

| About GlobalData

1 Colorectal Cancer: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 8MM Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of CRC

2.4.4 Forecast Assumptions and Methods: Diagnosed Incident Cases of CRC by AJCC Stage at Diagnosis

2.4.5 Forecast Assumptions and Methods: Diagnosed Incident Cases of CRC by Recurrence of Stages I–III into Stage IV Disease

2.4.6 Forecast Assumptions and Methods: Diagnosed Incident Cases of CRC by Molecular Markers

2.4.7 Forecast Assumptions and Methods: Five-Year Diagnosed Prevalent Cases of CRC

2.5 Epidemiological Forecast for CRC (2021–31)

2.5.1 Diagnosed Incident Cases of CRC

2.5.2 Age-Specific Diagnosed Incident Cases of CRC

2.5.3 Sex-Specific Diagnosed Incident Cases of CRC

2.5.4 Diagnosed Incident Cases of CRC by AJCC Stage at Diagnosis

2.5.5 Diagnosed Incident Cases of CRC by Recurrence of Stages I–III into Stage IV Disease

2.5.6 Diagnosed Incident Cases of CRC by Molecular Markers

2.5.7 Five-Year Diagnosed Prevalent Cases of CRC

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

List of Tables

Table 1: Summary of Newly Added Data Types

Table 2: Summary of Updated Data Types

Table 3: Risk Factors and Comorbid Conditions Associated with CRC

Table 4: 8MM, Diagnosed Incident Cases of CRC by Molecular Markers, Both Sexes, Ages ≥18 Years, N, 2021

List of Figures

Figure 1: 8MM, Diagnosed Incident Cases of CRC, Both Sexes, N, Ages ≥18 Years, 2021 and 2031

Figure 2: 8MM, Five-Year Diagnosed Prevalent Cases of CRC, Both Sexes, N, Ages ≥18 Years, 2021 and 2031

Figure 3: 8MM, Diagnosed Incidence of CRC, Men, Cases Per 100,000 Population, Ages ≥18 Years, 2011–31

Figure 4: 8MM, Diagnosed Incidence of CRC, Women, Cases Per 100,000 Population, Ages ≥18 Years, 2011–31

Figure 5: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of CRC

Figure 6: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Stage at Diagnosis

Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Recurrence into Stage IV Disease

Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers (KRAS Mutation, NRAS Mutation, BRAF Mutation, BRAF V600E Mutation, and PIK3CA/PTEN Mutation)

Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers (MSI-H/dMMR Molecular Subtype, HER2 Amplification, MET Amplification, and NTRK Gene Fusion)

Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers (DPYD, High TMB, Elevated CEA, and UGT1A1 Mutation)

Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers (POLE Mutation, TP53 Mutation, APC Mutation, and PD-L1 Expression on Tumors)

Figure 12: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of CRC

Figure 13: 8MM, Diagnosed Incident Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2021

Figure 14: 8MM, Diagnosed Incident Cases of CRC by Age, N, Both Sexes, 2021

Figure 15: 8MM, Diagnosed Incident Cases of CRC by Sex, N, All Ages, 2021

Figure 16: 8MM, Diagnosed Incident Cases of CRC by AJCC Stage at Diagnosis, N, All Ages, 2021

Figure 17: 8MM, Diagnosed Incident Cases of CRC by Recurrence of Stages I–III into Stage IV Disease, N, Both Sexes, Ages ≥18 Years, 2021

Figure 18: 8MM, Five-Year Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2021

Frequently Asked Questions

The total number of cases affected by colorectal cancer was 3,183,569 in 2021.

 

 

 

 

 

The total colorectal cancer cases is expected to grow at an AGR of more than 3% during the forecast period.

The key age segments in the colorectal cancer market are 18-29 years, 30-39 years, 40-49 ears, 50-59 years, 60-69 years, 70-79 years, >80 years. In 2021, for the 8MM combined, adults ages 70–79 years contributed the highest proportion of the diagnosed incident cases of CRC.

The key stages in the colorectal cancer market are stage I, stage II, stage III, and stage IV. In the 8MM, the highest number of diagnosed incident cases of CRC was in stage II, followed by stage III and stage I.

$3995

Can be used by individual purchaser only

$11985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.